• Healthy, as defined by the absence of any clinically significant medical condition or congenital anomaly as determined by medical history, physical examination, and clinical assessment of the investigator

• Parent(s) or guardian(s) willing and able to provide written informed consent prior to performance of any study-specific procedure

• Resides in study area and parent understands and is able and willing to adhere to all study visits and procedures (as evidenced by a signed informed consent form \[ICF\] and assessment by the investigator)

• Parent agrees for participant to receive all routine infant and childhood immunizations as per the approved protocol-adjusted schedule

• Male or female child from 1 to less than 5 years of age at the time of initial study vaccination

• Based on documentation, previously received a 3 or 4 dose primary poliomyelitis immunization series containing OPV (may have also received IPV), with last dose received more than 3 months prior to initial study vaccination

• Male or female infant expected to be 6 weeks of age (43rd to 49th day of life \[with day of birth being the first day of life\], inclusive+ 6-day window), at the time of initial study vaccination

• Prior to study vaccination has received no doses of IPV or OPV, based on no evidence of such vaccination per available documentation.

• Male or female newborn (1st day of life+ 3-day window, inclusive), at the time of initial study vaccination

• Prior to study vaccination has received no doses of IPV or OPV or rotavirus vaccine, based on no evidence of such vaccination per available documentation.